MedTrace Logo

A Study of TH-SC01 for Treating Complex Perianal Fistula in Perianal Crohn's Disease.

NCT04939337 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-06-25

No results posted yet for this study

Summary

The purpose of this study is to asses the efficacy and Safety of Allogeneic Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Complex Perianal Fistula in Perianal Crohn's Disease.

Conditions

Interventions

DRUG

TH-SC01

Allogeneic Umbilical Cord-derived Mesenchymal Stem cells perilesional injection. Human TH-SC01 cell injection (human umbilical cord mesenchymal stem cells for injection, 5 million cells / ml, 6.0-10.0ml / bottle)

Sponsors & Collaborators

  • Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Jinling Hospital, China

    lead OTHER

Principal Investigators

  • Wei Juan, doctor · Jinling Hospital, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-12
Primary Completion
2024-01-31
Completion
2024-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04939337 on ClinicalTrials.gov